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Abstract 
Background: This study explores thalassemia patients' perceptions concerning the effectiveness of conventional therapies for Thalassemia healthcare. 
Method: The semi-structured interviews were audiotaped, transcribed verbatim, and translated into English. Results: Nearly all thalassemia patients 
reported to have relied on conventional treatment methods to treat and reduce the severity of their disease. Few patients reported not to comply with 
their treatment procedures due to fear of infection through blood transfusion, surgery and organ failure. Conclusions: In conclusion, patients showed 
positive views about the conventional therapies carried out for Thalassemia.  
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1.0 Introduction 
Thalassemia disease is medically considered a genetic disorder. Those diagnosed with Thalassemia are chronically ill from birth and 
therefore are subject to conventional treatment, adhering to the procedures that may extend their lifespan. Many related studies 
addressing conventional treatment issues for thalassemia patients have been reported in the literature[ (Atkin, Ahmad, & Anionwu, 
1998). Thalassemia patients are categorized under a group classified as severe or chronic illness and use conventional medicine since 
birth. Concerning the prevalence of thalassemia disease, an estimated 2.5%-25% of the Mediterranean Basin, the Middle East, the 
tropical and subtropical regions of Africa, the Asian subcontinent, and Southeast Asia were reported diagnosed with it (Weatherall, 
2010). In Malaysia, 6,623 patients were registered with the Malaysian Thalassemia Registry as of 2014 (Hishamshah,2015). 
Thalassemia disease treatment always focuses on blood transfusion therapy, oral iron chelation therapy,  splenectomy, and other 
associated complications such as endocrinopathies and cardiac (Rachmilewitz & Giardina, 2011).In previous study showed that 68.5% 
thalassemia patients using CAM at least once during their life(Bordbar et.al,2017). Early complications may usually occur about blood 
transfusions while late complications occur due to iron overload and more importantly, the disease being treated poorly (Ismahanisa 
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Ismail, Ahmad Hassali, Mohamed Azmi, Maryam Farooqui, Fahad Saleem, 2016). The aims of this study was set to determine the 
perceptions the effectiveness use of conventional treatment among thalassemia patients. 
 
 
2.0 Materials and methods 
 
2.1 Study design and sampling method 
Joint ethical committees approved the study of the School of Pharmaceutical Sciences, USM and Lam Wah Ee Hospital on Clinical 
Studies in Malaysia [reference: USM-HLWE/IEC/2015 (002)]. The study was conducted from July until October in 2015 at the Kedah 
Thalassemia Society Centre, Alor Star, in Kedah, i.e., one of the four states in the northern region of Peninsular Malaysia. This centre 
was the place that thalassemia patients do their activities and counselling also getting information regarding thalassemia.  According to 
the Malaysian Thalassemia Registry 2014, the northern region recorded the highest number of thalassemia patients. In line with such a 
scope, purposive and theoretical samplings were employed to explore the issues with the perceptions of Thalassemia and its treatment 
used among thalassemia patients (Bordbar et.al,2017). Recruitment of patients was made until the researchers reached theoretical 
saturation, i.e., no new information emerged after the subsequent interviews, thus fulfilling theoretical sampling requirements(Auerbach 
& Silverstein, 2003). The participants were selected 18 years of age or older diagnosed with thalassemia disease and agreed to 
participate in this study. The interview sessions were administered until a saturation point was reached, i.e., no new information acquired 
from the following interviews.  Within the four months of recruiting thalassemia patients for the study, a total of 21 patients agreed to 
participate and were interviewed. It has to be noted that there were patients who could not participate in this study owing to health 
problems or were not accessible on the days when interviews were administered. 
 
2.2 Instrument and data collection 
The interview session was administered by adhering to the interview guide prepared based on a comprehensive review of previous 
studies. Participants were asked about issues that they could relate to thalassemia treatment. Open-ended questions were employed 
in the interview sessions to offer the patients the most outstanding possible chances to share their perspectives. At the beginning stage, 
a pilot study was carried out involving only four interview sessions to ensure any issues or barriers with the interview questions. That 
may assure that the study could be conducted accordingly and amend the interview guide if necessary(Kim, 2011). Each in-depth semi-
structured interview session lasted approximately 45 to 60 minutes. The interviews were conducted in the Malay language. Specifically, 
the interviews involved one patient for each session, with a total of 21 patients. At the 19th interview session, the saturation point was 
reached; however, two follow-up interviews had to be conducted to triangulate the findings. The interview sessions were recorded 
digitally and were transcribed in English by the principal investigator. The patients were categorized with unique numbers (P01-P21) to 
assure that participants' identities were kept confidential. The principal investigator, who is the head of this research project was present 
in the entire interview sessions. The interview sessions were transcribed verbatim. The transcripts were reviewed by the researchers 
and were subsequently sent to the patients for member-checking purposes. The transcripts were subjected to thematic content analysis, 
including coding and identifying the comparative analytic process to determine the emerging categories. This was jointly carried out by 
the principal investigator and the co-researchers who were notified of this study's aims and objectives. The principal investigator and 
the patients in the study shared a similar cultural background, i.e., they spoke Malay in the Kedahan dialect and English. Therefore, 
communication barriers did not stand in their way. The data was further analysed to assess the behaviour of each participant based on 




A total of twenty-one patients (P01-P21) between the ages of 18 and 58 (Mean = 29 years) were interviewed.  As the Malays constitute 
the leading ethnic group in Malaysia, they made up the highest (n=17) number of patients in the sampled group of patients, followed by 
the Chinese (n=4).  Most of the patients were from a low-income group seeking treatment in government hospitals.  It was discovered 
that all the patients belonged to either β thalassemia major or intermediate thalassemia. Seeking treatment at private hospitals may not 
be a sensible move as almost no insurance companies cover thalassemia patients' medical cost. Therefore, these patients had no other 
choice than seeking treatment at government hospitals. The demographic data of the patients are summarized in Table 1. The 
conventional treatment offered by hospitals includes blood transfusion, surgery and chelation therapy. It is noteworthy that traditional 
healing methods may consist of any treatment other than what is being provided by the hospitals. Thematic content analysis revealed 
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Table 1: Demographic and clinical characteristic of participant 
 
3.1 Perceived Effectiveness of Conventional Treatment 
It is noteworthy that for the past 40 years, the treatment for Thalassemia in Malaysia has significantly improved and patients are satisfied 
with the services offered during the treatment compared to previous years. Blood transfusion is the mainstay of thalassemia treatment 
for individuals with either intermedia or major. It is needed to prevent the growth of body, skeletal and endocrinologic complications in 
thalassemia major. This is because the patients need to seek necessary treatment to continue their life as they do not have any other 
options. Following the blood transfusion, the patients will continue with chelation therapy because the blood transfusion will increase the 
gastrointestinal absorption, which leads to the overloading of iron. The overload iron is the cause of morbidity and mortality in 
Thalassemia. 
Thalassemia patients perceive that the treatments were adequate because the disease symptoms were reduced after their 
treatment, such as reduced ferritin levels and increased haemoglobin levels. Following are the responses from the patients: 
 
"I think that modern treatment is good and effective for my sickness". [P1, 38 years, Female, Malay, Thalassemia  intermedia] 
 
"I believe in the effectiveness of modern treatment because it works faster and is more effective even though those suffering from 
Thalassemia cannot be cured. Modern treatment comes with evidence from research compared to the lack of evidence from the traditional 
ones. Today, the current conventional treatment is more effective compared to that of the previous years". [P10, 23 years, Female, Malay, 
β-Thalassemia Major] 
 
Therefore, the patients deemed that conventional treatment can reduce the sickness rather than doing nothing. 
 
3.2 Perceived Evidence from the Research 
The conventional treatments of Thalassemia provided by the hospital have improved. The sampled patients perceived that these 
treatments, which were done by experimental, can be described as safe, expensive, advanced and can. The sampled patients perceived 
that these treatments, which were done by experimental, can be described as safe, expensive, progressive and can cure or reduce the 
symptoms. Moreover, the patients perceived that the iron-chelating process reduces the iron loading inside their body because iron   
accumulation in the tissues causes the progressive organ to dysfunction and may cause fatal. It should be noted that patients need to  
follow all the therapy to prevent complications. Following were the patients' responses:  
 
I feel that modern treatments respond faster than traditional treatments, helping me live my life as usual.[Patient 9:  19years, Female, Malay, 
Thalassemia intermedia] 
 
Feels and believes that modern medicine works for those with Thalassemia. They respond faster compared to traditional treatments. The 
expert does the modern treatments, and they establish by continuous research compare to the traditional [Patient 7:  29yrs, Female, Malay, 
Thalassemia intermedia] 





Educational background Currently 
Using CAM 
Type of Thalassemia 
P01 39  Female  Malay Islam Married Middle Secondary YES Intermediate Thalassemia 
P02 27  Male  Malay Islam Unmarried low Secondary YES β-Thalassemia major 
P03 32  Female  Malay Islam Widowed low Secondary YES Intermediate Thalassemia 
P04 25  Female  Malay Islam Unmarried low Diploma/Matriculation YES β-Thalassemia major 
P05 23  Female  Malay Islam Unmarried low Secondary YES β-Thalassemia major 
P06 30  Female  Malay Islam Married Middle Secondary YES Intermediate Thalassemia 
P07 32  Female  Malay Islam Unmarried Middle Diploma/Matriculation YES Intermediate Thalassemia 
P08 32  Female  Malay Islam Married Middle Secondary YES Intermediate Thalassemia 
P09 20  Female  Malay Islam Unmarried low Secondary YES Intermediate Thalassemia 
P10 24  Female  Malay Islam Unmarried low Secondary YES β-Thalassemia major 
P11 21  Female  Malay Islam Unmarried Middle Diploma/Matriculation YES β-Thalassemia major 
P12 32  Female  Malay Islam Unmarried low Secondary YES β-Thalassemia major 
P13 31  Male  Malay Islam Unmarried low Secondary YES β-Thalassemia major 
P14 23  Female  Malay Islam Unmarried low Certificate MARA YES Intermediate Thalassemia 
P15 25  Male  Malay Islam Unmarried low Secondary YES β-Thalassemia major 
P16 27  Female  Malay Islam Unmarried Middle Diploma/Matriculation YES β-Thalassemia major 
P17 23  Male  Malay Islam Unmarried low Diploma/Matriculation YES β-Thalassemia major 
P18 58  Male  Chinese Buddhism Married low Primary NO Thalassaemia carrier 
P19 20  Male  Chinese Buddhism Unmarried low Secondary NO Thalassaemia carrier 
P20 38  Male  Chinese Buddhism Married Middle Diploma/Matriculation YES Thalassaemia carrier 
P21 39  Female  Chinese Buddhism Married Middle Secondary YES Thalassaemia carrier 
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These patients deemed that the expensive, highly sophisticated and advanced technology treatments may reduce their illness and 
problems. 
 
"I believe in the effectiveness of modern treatment because it works faster and is very expensive. Before this, we had to buy our filter bag, 
unlike these days. It is more effective even though those suffering from Thalassemia cannot be cured". [P10, 23 years, Female, Malay, β-
Thalassemia Major] 
 
3.3 Fear of the effects of conventional treatment. 
Some thalassemia patients who were chronically ill and underwent conventional treatment shortly after giving birth may persist the 
illness until death. Although many treatments are deemed beneficial, thalassemia patients still felt that the treatments are associated 
with risks. 
 
3.3.1 Fear of blood transfusion 
Some of the patients developed fear on the continuous blood transfusion as it may lead to iron overload and risk of bacterial and viral 
infections. 
 
"For the blood transfusion, I am a bit worried whenever I think of the possible risks of getting infected with HIV and many more. But, gradually, 
I have got used to it. Now, whenever it crosses my mind, I quickly pray and hope for the best". [P12, 32 years, Female, Malay, β-Thalassemia 
Major] 
 
"Antibiotics don't work. I am still sick. I had to be warded for five months, unconscious due to brain infection or brain abscess. The doctor, 
said that it was because of the blood transfusion done on me". [P1, 38 years, Female, Malay, Thalassemia  intermedia] 
"Each time I had to do the blood transfusion, I am worried that I will get infected by HIV and hepatitis C ". [Patient 2:  26years, Male, Malay, 
β-Thalassemia Major] 
 
"My liver often swells maybe due to the frequent blood transfusion each month. My spleen often swells too. Sometimes I wonder if I keep 
on doing blood transfusion, am I going to be infected with  Hepatitis C virus for example, because many of those with Thalassemia got 
hepatitis C". [P5, 22 years, Female, β-Thalassemia Major] 
 
The sampled thalassemia patients were worried about the conventional treatment's inherent long-term adverse effects, potentially 
life-threatening. The sampled patients were also sceptical about the severe co-morbidities such as hepatic fibrosis, cirrhosis, pulmonary 
dysfunction, multiple endocrinopathies and growth failure. These were the concerns among thalassemia patients every time they need 
to do a blood transfusion. 
 
3.3.2 Fear of iron chelation therapy 
The sampled participants were concerned about the problem involving the long term chelation therapy. An iron chelator is required in 
these patients following 10-20 units of packed red blood cells or the serum ferritin, which is more than 1000ng/mg. They were concerned 
about the continuous chelator therapy effect, which defers from the healthcare providers' instructions. The patients were reportedly 
suffered from side effects after the consumption of exjade, including pain, itchiness and swelling at the injection site. It is noteworthy 
that these have made the patients to ignore and missed the consumption of exjade. This is evident in the participant's responses below: 
 
"I  frequently vomit after taking exjade and then changed to L1. Injecting dysferal causes my skin to itch. My spleen had been removed. 
Then I took penicillin. I am easily tired because I have to take injections often. I often tried to escape from getting treatments until I am not 
well. If I take medicines, I will sleep all day because the medicines make me feel sleepy. It is very tiring and boring to inject my self every 
day and every night. Any alternative treatment, I will try it because I do not want to continue this treatment my whole life and keep on 
depending on medicines. I do not want it to interfere with my life". [P15, 24 years, Male, Malay, βThalassemia Major] 
 
 "Having injected dysferal four bottles a day for six days straight sometimes makes me difficult to move, and my skin would become itchy".    
  [P10, 23 years, Female, Malay, β-Thalassemia Major] 
 
Inject dysferal four bottles a day for six days straight, and sometimes it made me difficult to move, and my skin got itchy. I also got ulcers 
often but do not because of what or which medicines. Sometimes I think of changing blood, but I must be brave and willing to take risks to 
live. [Patient 10: 23years, Female, Malay, β -Thalassemia Major] 
 
Based on the participant's responses, the common reason for the unwillingness to go for iron chelation treatment was the side 
effects. As a result, the patients opt for complementary and alternative medicine to replace iron chelation treatment. 
 
3.3.3 Fear of surgery 
The sampled patients were afraid after their first surgery of spleen. After years of undergoing blood transfusion, the patients will 
experience a splenectomy. This happens when the patients are required to have a transfusion which is more than 200ml packed cell 
per kilogram body weight, and this may have a significant effect in diminishing the iron accumulation. The patients were afraid of the 
potential of hepatitis and other infections during the blood transfusion procedure, especially after spleen removal. They were also 
concerned about removing the liver after spleen surgery because it may enlarge after the regular blood transfusion. 




"I had to remove my spleen because it had been swollen due to the continuous blood transfusion done on me". [P8, Female, Malay, β-
Thalassemia Major] 
 
"But if I can get better treatment, for instance, the traditional way, I would stop undergoing the treatment I am doing now as I am not sure of 
its consequences if I continue with this treatment". [P13, 30 years, Male, Malay, β-Thalassemia Major] 
 
The fear of side effects of the treatments may result in the patients' unwillingness to comply with the conventional treatment, which 
has resulted in the usage of complementary and alternative medicine as therapies. However, the concurrent use of CAM with 
conventional treatment may enhance or reduce the conventional medicines' side effects. Furthermore, proper counselling and ongoing 
education between the health practitioners and noncompliant patients and reduced side effects on conventional medicine are deemed 




This study aimed to look into the perceptions and experience of conventional treatment within a group of thalassemia patients. Studying 
the patients' perceptions about conventional treatment is of utmost importance as the findings may inform if they comply with or forgo 
the treatment procedures. Conventional treatment because this treatment only can prolonged their life .However , when taking blood 
transfusion they also can suffer from complication(Borgna et.al, 2017) .In the present study, the patients perceived that the conventional 
treatment was beneficial and effective in reducing the severity of Thalassemia. Clinical features and management of Thalassemia have 
presently improved considerably with the advanced and sophisticated technologies being incorporated compared to the 
past(Cunningham, Macklin, Neufeld, Cohen, & Thalassemia Clinical Research Network, 2004). However, significant effects from such 
methods on patients have yet to be seen. The thalassemia patients sampled in this study reported that they fear conventional treatment 
effects such as blood transfusion, fear of iron chelation therapy and surgery. Individuals belonging to the category of thalassemia major 
usually undergo comprehensive conventional treatment for a lifetime. However, the regular blood transfusion may enhance the iron 
overload in various endocrine organs and form alloantibodies after the multi transfused blood procedures(Dogra, Sidhu, Kapoor, & 
Kumar, 2015; W. ismahanisa Ismail, Al-Hassan, & Shatar, 2016; Jensen et al., 1998). 
Moreover, these patients also raised concerns about potentials infections that they may suffer from blood transfusions such as 
hepatitis, HIV and other infectious diseases. It has been reported that thalassemia patients who received multiple blood transfusion can 
cause the risk of seroconversion of hepatitis B and hepatitis C virus (Lee, Teh, & Chan, 2005). The iron overload in the patients' body 
may have to be removed using iron-chelating therapy. The patients' fear of the chelation process could be due to the local side effects 
resulting from the treatment using deferoxamine. 
 The treatment of iron overload is often associated with complications about the growth of deficiency, delayed puberty, 
hypothyroidism, diabetes and osteoporosis (Galanello & Origa, 2010). Previous studies reported in the literature showed that traditional 
and complementary medicine, lack of family support, technical problems, and limited access to healthcare programs contribute to 
noncompliance with this chelation agent. The patients preferred the use of deferasirox compared to deferoxamine as it can be consumed. 
Still, it has to be highlighted that the deferoxamine is much cheaper and more effective in reducing iron overload (Cunningham et al., 
2004; Lee, Toh, Chai, & Soo, 2011) deferoxamine is provided at government hospitals in Malaysia for free of charge. Though notably 
cheaper the patients' noncompliance about using deferoxamine, the cost of deferoxamine may result in complications and therefore 
may involver higher cost to treat the patients who have problems(Delea et al., 2007; Fisher et al., 2013). The thalassemia patients also 
admitted that they feared the splenectomy's surgery and was afraid of the second surgery because their liver may swell. Post-
splenectomy infection and the splenectomy risk may generally delay until more than five years (Olivieri & Brittenham, 1997). However, 
the splenectomy may happen to thalassemia patients to avoid the splenic enlargement, leukopenia, or other thrombocytopenia and iron 
overload despite useful chelation(Borgna Pignatti& Cappellini, 2005; Galanello & Origa, 2010).Nevertheless this study have several 
limitations , the respondents of this study from low income and middle class group of people.It should conduct also among thalassemia   
patients with high income group to determine whether they are using CAM only as alternative or as compliment to the thalassemia 
treatment .Further analysis of the thalassemia patients may have to be carried out to avoid the noncompliance and delay seeking 
treatment. Failing to seek appropriate treatment for this disease at an early stage may result in complications going unnoticed. Lives of 
these patients may end fatally (A. Ismail, Campbell, Ibrahim, & Jones, 2006; Wan Ismahanisa Ismail et al., 2016; Ismail, Ahmad Hassali, 
Farooqui, Saleem, & Roslan, 2018)). 
 
 
5.0 Conclusions & Recommendations 
Based on the present study's findings, the researchers concluded that these patients perceived the benefits and the effectiveness of 
conventional medicine. They were persuaded to comply with the treatments diligently and consistently consuming their drugs. It should 
be noted that the patients should not miss even a single dose of their medication as it may bring negative implications. However, some 
patients with different perspectives view some patients with different views from different conventional treatment perspectives. They 
were worried and were afraid of pre and post-treatment effects. The present study's findings also provide some understanding and views 
among thalassemia patients regarding modern treatment. This information is pivotal in designing effective educational and intervention 
programmes such as counselling between the healthcare providers and the patients to know the problem and come out with solutions 
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to overcome these problems. The level of good compliance with the medication may be challenging in the population of the present 
study. Still, it is essential to avoid early mortality among thalassemia patients. Since patient showed dissatisfaction towards conventional 
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